Characteristics of headache | New type of headache | P, OR, 95% CI | Headache with altered characteristics | P, OR, 95% CI | ||
---|---|---|---|---|---|---|
Headache at the onset of stroke (n = 46) | Headache in three months after stroke (n = 34) | Headache at the onset of stroke (n = 30) | Headache in three months after stroke (n = 21) | |||
Frequency of headache per month | ||||||
First month | ||||||
1–7 days | n/aa | 7 (20.6%) | n/a | 4 (19.0%) | ||
8–14 days | n/a | 14 (41.2%) | n/a | 9 (42.9%) | ||
≥ 15 days | n/a | 13 (38.2%) | n/a | 8 (38.1%) | ||
Second month | ||||||
1–7 days | n/a | 11 (32.4%) | n/a | 5 (23.8%) | ||
8–14 days | n/a | 13 (38.2%) | n/a | 8 (38.1%) | ||
≥ 15 days | n/a | 10 (29.4%) | n/a | 8 (38.1%) | ||
Third month | ||||||
1–7 days | n/a | 13 (38.2%) | n/a | 6 (28.6%) | ||
8–14 days | n/a | 12 (35.3%) | n/a | 7 (33.1%) | ||
≥ 15 days | n/a | 9 (26.5%) | n/a | 8 (38.1%) | ||
Intensity | ||||||
Mild | 1 (2.2%) | 0 (0%) | 0.4 | 2 (6.7%) | 0 (0%) | 0.2 |
Moderate | 14 (30.4%) | 13 (38.2%) | 0.5 | 11 (36.7%) | 12 (57.1%) | 0.1 |
Severe | 31 (67.4%) | 21 (61.8%) | 0.6 | 17 (56.7%) | 9 (42.9%) | 0.3 |
Duration | ||||||
< 1 h | 4 (8.7%) | 0 (0%) | 0.08 | 0 (0%) | 0 (0%) | - |
1–4 h | 1 (2.2%) | 0 (0%) | 0.4 | 0 (0%) | 0 (0%) | - |
5–23 h | 17 (37.0%) | 13 (38.2%) | 0.9 | 13 (43.3%) | 9 (42.9%) | 0.9 |
1–3 days | 24 (52.2%) | 21 (61.8%) | 0.4 | 17 (56.7%) | 12 (57.1%) | 0.9 |
Aggravation by routine physical activity | 31 (67.4%) | 27 (79.4%) | 0.2 | 24 (80.0%) | 15 (71.4%) | 0.5 |
Accompanying symptoms | ||||||
Nausea | 22 (47.8%) | 18 (52.9%) | 0.7 | 9 (30.0%) | 10 (47.6%) | 0.2 |
Vomiting | 13 (28.3%) | 5 (14.7%) | 0.2 | 5 (16.7%) | 0 (0%) | 0.049; OШ нeт |
Photophobia | 15 (32.6%) | 5 (14.7%) | 0.07 | 9 (30.0%) | 1 (4.8%) | 0.03; 8.0; 1.0–33.7 |
Phonophobia | 11 (23.9%) | 2 (5.9%) | 0.03; 5.0; 1.0–24.4 | 7 (23.3%) | 1 (4.8%) | 0.07 |
Aura | 1 (2.2%) | 1 (2.9%) | 0.8 | 0 (0%) | 0 (0%) | - |
Location | ||||||
Frontal | 16 (34.8%) | 10 (29.4%) | 0.6 | 11 (36.7%) | 8 (38.1%) | 0.9 |
Temporal | 21 (45.7%) | 15 (44.1%) | 0.9 | 16 (53.3%) | 9 (42.9%) | 0.5 |
Frontotemporal | 12 (26.1%) | 15 (44.1%) | 0.09 | 9 (30.0%) | 7 (33.3%) | 0.8 |
Occipital | 18 (39.1%) | 9 (26.5%) | 0.2 | 17 (56.7%) | 4 (19.0%) | 0.007; 4.4; 1.3–14.6 |
Parietal | 16 (34.8%) | 3 (8.8%) | 0.007; 5.5; 1.5–20.9 | 7 (23.3%) | 1 (4.8%) | 0.07; 5.9; 0.7–50.6 |
Hemicrania | 10 (21.7%) | 2 (5.9%) | 0.05; 4.4; 0.9–21.8 | 3 (10.0%) | 1 (4.8%) | 0.5 |
Side | ||||||
Unilateral | 23 (50.0%) | 5 (14.7%) | 0.001; 5.8; 1.9–17.6 | 6 (20.0%) | 4 (19.0%) | 0.9 |
Right | 14 (30.4%) | 3 (8.8%) | 0.02; 4.5; 1.2–17.3 | 2 (6.7%) | 2 (9.5%) | 0.7 |
Left | 9 (19.6%) | 2 (5.9%) | 0.08 | 4 (13.3%) | 2 (9.5%) | 0.7 |
Bilateral | 22 (47.8%) | 27 (79.4%) | 0.004; 0.2; 0.1–0.7 | 24 (80.0%) | 16 (76.2%) | 0.7 |
Alternating from one attack to the next | 1 (2.2%) | 2 (5.9%) | 0.4 | 0 (0%) | 1 (4.8%) | 0.2 |
Simple analgesics ≥ 15 days per month | n/a | 8 (23.5%) | 2 (6.7%) | 3 (14.3%) | 0.4 | |
Combine analgesics ≥ 10 days per month | n/a | 4 (11.8%) | 1 (3.3%) | 5 (23.8%) | 0.03; 0.1; 0.01–1.2 | |
Triptans ≥ 10 days per month | n/a | 0 (0%) | 1 (3.3%) | 0 (0%) | 0.4 |